Literature DB >> 33707836

Comparison of Clinical Features Between Primary and Secondary Breast Diffuse Large B Cell Lymphoma: A Yokohama Cooperative Study Group for Hematology Multicenter Retrospective Study.

Hiroyuki Takahashi1, Rika Sakai1, Takayuki Sakuma1, Ayako Matsumura1, Kazuho Miyashita2, Yoshimi Ishii2, Yuki Nakajima2, Ayumi Numata2, Yukako Hattori3, Takuya Miyazaki4, Chizuko Hashimoto3, Hideyuki Koharazawa5, Sachiya Takemura6, Jun Taguchi5, Katsumichi Fujimaki7, Hiroyuki Fujita8, Hideaki Nakajima4.   

Abstract

We performed a retrospective analysis of DLBCL with breast involvement to compare the prognosis of primary breast lymphoma (PBL) to secondary breast lymphoma (SBL; especially in limited stage cases). We retrospectively reviewed records of 25 diffuse large B-cell lymphoma (DLBCL) patients with breast involvement who received chemotherapy between January 2000 and August 2012. We compared clinical features and prognosis among patients with PBL (n = 11), limited stage SBL (LSBL; n = 6), and advanced stage SBL (ASBL, n = 8). The PBL group had significantly lesser patients with breast tumours (BTs) > 5 cm than the SBL group (P = 0.02). After a median follow-up of 71.3 months, we observed significantly better 5-year overall survival (OS) in the PBL group (90.0%) than in the LSBL (33.3%, P = 0.01) group, but not for progression-free survival (PFS). Patients with BT > 5 cm had worse OS (P = 0.01) and PFS (P = 0.04) than those with BT ≤ 5 cm. PBL had a better prognosis than SBL among limited stage DLBCL. © Indian Society of Hematology and Blood Transfusion 2020.

Entities:  

Keywords:  Breast tumor; Diffuse large B-cell lymphoma; Primary breast lymphoma; Secondary breast lymphoma

Year:  2020        PMID: 33707836      PMCID: PMC7900317          DOI: 10.1007/s12288-020-01307-7

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  14 in total

Review 1.  Primary breast lymphoma.

Authors:  Chan Y Cheah; Belinda A Campbell; John F Seymour
Journal:  Cancer Treat Rev       Date:  2014-06-06       Impact factor: 12.111

2.  Primary lymphoma of the breast.

Authors:  C Wiseman; K T Liao
Journal:  Cancer       Date:  1972-06       Impact factor: 6.860

3.  Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution.

Authors:  Suguru Fukuhara; Takashi Watanabe; Wataru Munakata; Masakazu Mori; Dai Maruyama; Sung-Won Kim; Yukio Kobayashi; Hirokazu Taniguchi; Akiko M Maeshima; Ryuji Tanosaki; Yoshihiro Matsuno; Kensei Tobinai
Journal:  Eur J Haematol       Date:  2011-08-19       Impact factor: 2.997

4.  Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era.

Authors:  Naoto Tomita; Masahiro Yokoyama; Wataru Yamamoto; Reina Watanabe; Yutaka Shimazu; Yasufumi Masaki; Saburo Tsunoda; Chizuko Hashimoto; Kayoko Murayama; Takahiro Yano; Rumiko Okamoto; Ako Kikuchi; Kazuo Tamura; Kazuya Sato; Kazutaka Sunami; Hirohiko Shibayama; Rishu Takimoto; Rika Ohshima; Yoshihiro Hatta; Yukiyoshi Moriuchi; Tomohiro Kinoshita; Masahide Yamamoto; Ayumi Numata; Yoshiaki Ishigatsubo; Kengo Takeuchi
Journal:  Cancer Sci       Date:  2011-11-29       Impact factor: 6.716

5.  Investigation of the freely available easy-to-use software 'EZR' for medical statistics.

Authors:  Y Kanda
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

6.  Clinicopathologic features and treatment outcome of non-Hodgkin lymphoma of the breast--a review of 42 primary and secondary cases in Taiwanese patients.

Authors:  Yu-Chin Lin; Chung-Hsin Tsai; Jia-Shing Wu; Chiun-Sheng Huang; Sung-Hsin Kuo; Chung-Wu Lin; Ann-Lii Cheng
Journal:  Leuk Lymphoma       Date:  2009-06

7.  Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma.

Authors:  Nozomi Niitsu; Masataka Okamoto; Hirokazu Nakamine; Masami Hirano
Journal:  Leuk Res       Date:  2008-05-19       Impact factor: 3.156

8.  Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group.

Authors:  G Ryan; G Martinelli; M Kuper-Hommel; R Tsang; G Pruneri; K Yuen; D Roos; A Lennard; L Devizzi; S Crabb; D Hossfeld; G Pratt; M Dell'Olio; S P Choo; R G Bociek; J Radford; S Lade; A M Gianni; E Zucca; F Cavalli; J F Seymour
Journal:  Ann Oncol       Date:  2007-10-11       Impact factor: 32.976

9.  Primary breast diffuse large B-cell lymphoma: a population-based study from 1975 to 2014.

Authors:  Yijun Jia; Chenbo Sun; Zebing Liu; Weige Wang; Xiaoyan Zhou
Journal:  Oncotarget       Date:  2017-12-08

10.  Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure.

Authors:  Shaoxuan Hu; Yuqin Song; Xiuhua Sun; Liping Su; Wei Zhang; Jing Jia; Ou Bai; Sheng Yang; Rong Liang; Xiaoling Li; Huilai Zhang; Yuhuan Gao; Weijing Zhang; Xiubin Xiao; Huizheng Bao; Ningju Wang; Hanyun Ren; Xinan Cen; Shun'e Yang; Yu Zhao; Yinan Wang; Yalan Wang; Aichun Liu; Jingwen Wang; Yuankai Shi; Ming Yuan; Yufu Li; Xiaohui He
Journal:  Cancer Sci       Date:  2018-11-11       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.